PDCD1 and small cell lung carcinoma: This result has been continuously verified by similar drugs in SCLC, and then Serplulimab has demonstrated for the first time that PD-1 monoclonal antibody can also prolong survival in ASTRUM-005 study,8 which is mainly in Chinese ES-SCLC patients.